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ABSTRACT:
Molybdenum cofactor deficiency is a rare degenerative brain disorder with autosomal recessive inheritance. It presents
early in neonatal life with seizures, feeding difficulty and spasticity, sometimes misdiagnosed as neonatal hypoxic
ischemic encephalopathy. Neuroimaging findings are consistent with loss of white matter and volume along with cystic
encephalomalacic changes. Most of the patients have mutations in the MOCS1 and MOCS2 genes causing imbalance
in the sulfur-containing amino acid metabolism leading to progressive neurological damage and early childhood death
in majority of cases. We report a case of a 7 months old child, product of non-consanguineous marriage with history
of neonatal seizures and global developmental delay. Examination showed facial dysmorphism and spasticity with
neuroimaging showing marked cortical atrophy and agenesis of corpus callosum.
KEY WORDS: Molybdenum cofactor deficiency, MOCS1, MOCS2, neonatal seizures
INTRODUCTION:
Molybdenum cofactor deficiency (MoCo) is a rare
neuro-degenerative condition which is inherited in an
autosomal recessive pattern. It is characterized by
neonatal seizures, which often become refractory,
feeding difficulties, facial dysmorphism, spasticity and
opisthotonic posturing along with global developmental
delay and cerebral atrophy. Molybdenum is involved in
the functioning of four different enzymes including
sulfite oxidase, aldehyde oxidase, xanthine oxidase,
and mitochondrial amidoxime reducing component
(mARC), each harboring the pterin-based molybdenum
cofactor (MoCo).1 Of these enzymes, sulfite oxidase is
known to be crucial for neurological functioning. The
common mutations leading to MoCo deficiency have
been identified in the genes MOCS1 (type A), MOCS2
(type B) and rarely GPHN (type C).2 Genetic mutation
results in the loss of sulfite oxidase activity leading to
buildup of certain chemicals, including sulfite and
S-sulfocysteine that causes severe neurologic
dysfunction in the affected individuals. MoCo deficiency
also affects the xanthine pathway leading to an
accumulation of hypoxanthine and xanthine, and low to
undetectable uric acid levels in blood.3
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FIG 1: Molybdenum Cofactor Biosynthesis

Abbreviations: MOCS (Molybdenum Cofactor Synthesis
Protein), GPHN (Gephyrin Protein)
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CASE REPORT
A 7 months old boy, product of a non-consanguineous
marriage but with significant deaths and miscarriages
on the paternal side, 2nd in order in a family of 2
siblings, born at term to a healthy mother. There was
significant antenatal history of mild polyhydramnion
and brain anomaly was detected on 36 weeks
gestational scan showing ventriculomegaly. The baby
had immediate cry and was born with an APGAR score
of 9 at 1 min and 5 min. Physical examination showed
normal facies, birth weight of 2.8kg (10th centile),
length of 51cm (50th centile) and head circumference
of 33.5cm (10th centile). He was admitted in the
nursery for four days because of poor suckling and
multi-focal clonic and tonic seizures. MRI brain on 2nd
day of life showed severe brain atrophy, agenesis of
corpus
callosum,
bilateral
symmetical
T1W
hyperintense signals in basal ganglia, cystic
enlargement in posterior fossa and giant cisterna
magna. Seizures were controlled with medication
namely levetiracetam at 40mg/kg/day and child was
discharged on 5th day of life. At 2nd month of age the
child developed inconsolable cry, arching episodes and
opisthotonic posture for which he was started on
muscle relaxant tizanidine 1 mg/day and clonazepam
0.2mg/day. At 7 months follow up, child had delayed
milestones, microcephaly with overriding of sutures,
facial dysmorphism which was initially not present,
spasticity in all four limbs and severe muscle wasting.
On reviewing the family tree, there was death of a
previous child and multiple miscarriages from the first
consanguineous marriage of father. Although this child
was a product of a non-consanguineous marriage, but
considering the paternal history and early presentation,
feeding issues, seizures and cerebral atrophy of this
child, genetic work up was done.

FIG 2:Cortical atrophy and ventriculomegaly

FIG 3: Bilateral T1W hyperintensities in basal ganglia

FIG 4: Arachnoid cyst (Blue arrow) Agenesis of
corpus callosum (Green arrow)
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type B deficiency (MOCS2 gene) do not lack this
molecule, hence they cannot benefit from this
treatment. However, supplementation with pyridoxine
could reduce the frequency of seizures in these
patients.11 The deficiency can also be diagnosed
prenatally by monitoring the sulfite oxidase activity on
chorionic villous sampling tissue and subsequent
mutational analysis can be done.12 Although
therapeutic options are yet to be ascertained, early
detection and genetic testing in such degenerating
brain disorder is important for genetic counselling.13

His whole exome sequencing revealed a missense
homozygous pathogenic variant in the MOCS2 gene
causing an amino acid change from Gly to Arg at
position 76 as shown in Table 1 and genetic diagnosis
of autosomal recessive Molybdenum cofactor
deficiency type B was confirmed despite a
non-consanguineous marriage. His uric acid level was
low (<1 mg/dl; Range: 2-5mg/dl) which corresponded
with the disease. At present at the time of case report,
child is 15 month old, thriving well with weight of 10 kg
(50th centile), OFC of 47 cm (between 25th – 50th
centile). He having global developmental delay with no
gaze fixation or neck holding, poor auditory and feeding
difficulties. His seizures are well controlled but there is
spasticity which is also improved. Nature of genetic
origin has been explained to the family.

Our case report emphasizes that refractory neonatal
seizures without a clear documented hypoxic ischemic
event, progressive microcephaly, spasticity and specific
neuroimaging findings can be clinical clues to early
diagnosis. Even in the absence of consanguinity, in the
families where there are unexplained death and
miscarriages, a high index of suspicion is needed as
most cases are otherwise labelled as hypoxic ischemic
encephalopathy and managed as cerebral palsy. Thus,
a genetic diagnosis is mandatory and important for
genetic counselling.

TABLE: Results of Genetic Testing
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DISCUSSION
Molybdenum cofactor deficiency is a rare autosomal
recessive condition of sulfur-containing amino acid
metabolism. It has an estimated prevalence of 1 in
100,000 to 200,000 newborns worldwide 4 and nearly
only 100 cases have been reported in literature.5 It
classically occurs in early infancy with majority of
patients presenting with epileptic encephalopathy
along with feeding difficulties and facial dysmorphism6
like our index case, although late presentation with
global developmental delay including motor, visual and
language impairment7 and atypical presentation with
movement disorder have also been described.8 Typical
neuroimaging findings include loss of white matter and
volume, cystic encephalo-malacic changes and
ventriculomegaly but novel findings of agenesis of
corpus callosum and interhemispheric cyst similar to
our index case have also been reported.3 MoCo
deficiency has overlapping phenotypic features with
sulfite oxidase deficiency and is sometimes
differentiated only biochemically by low serum uric acid
concentrations due to loss of function of xanthine
dehydrogenase in MoCo defiency.3 Clinical features can
also be mistaken for neonatal hypoxic ischemic
encephalopathy6,9 and children presenting late with
spastic quadriplegia and intellectual disability are
usually labelled as cerebral palsy. Treatment with
exogenous cyclic pyranopterin monophosphate (cPMP)
for type A deficiency is present.10 Since patients with
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